본문으로 건너뛰기
← 뒤로

Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis.

1/5 보강
American journal of hematology 2026 Chronic Myeloid Leukemia Treatments
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-04-29
OpenAlex 토픽 · Chronic Myeloid Leukemia Treatments Acute Lymphoblastic Leukemia research Chronic Lymphocytic Leukemia Research

Sasaki K, Kantarjian H, Rausch CR, Goulart H, Jain N, Huang X, Hachem M, Wierda WG, Kadia TM, Borthakur G, Issa GC, Alvarado Y, Pemmaraju N, Garris R, Ravandi F, Garcia-Manero G, Short NJ, Jabbour E

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Koji Sasaki, HM Kantarjian, et al. (2026). Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis.. American journal of hematology. https://doi.org/10.1002/ajh.70325
MLA Koji Sasaki, et al.. "Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis.." American journal of hematology, 2026.
PMID 42031676
DOI 10.1002/ajh.70325

같은 제1저자의 인용 많은 논문 (5)